Holen Sie sich die Stockscreener-App
88.14
0.79%
0.69
Handel nachbörslich:
88.14
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$87.45
Offen:
$87.64
24-Stunden-Volumen:
4.36M
Relative Volume:
1.15
Marktkapitalisierung:
$42.85B
Einnahmen:
$6.13B
Nettoeinkommen (Verlust:
$272.21M
KGV:
159.64
EPS:
0.5521
Netto-Cashflow:
$1.38B
1W Leistung:
+0.51%
1M Leistung:
+3.57%
6M Leistung:
+10.37%
1J Leistung:
+34.30%
1-Tages-Spanne:
$87.09
$88.62
1-Wochen-Bereich:
$87.09
$91.06
52-Wochen-Spanne:
$61.76
$91.06
Ventas Inc Stock (VTR) Company Profile
Firmenname
Ventas Inc
Sektor
Telefon
(312) 660-3800
Adresse
300 N LASALLE STREET, CHICAGO, IL
Compare VTR vs WELL, OHI, DOC, CTRE
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VTR
Ventas Inc
|
88.14 | 42.52B | 6.13B | 272.21M | 1.38B | 0.5521 |
WELL
Welltower Inc
|
212.61 | 150.88B | 11.75B | 1.46B | 2.19B | -0.6014 |
OHI
Omega Healthcare Investors Inc
|
48.32 | 14.09B | 1.24B | 655.98M | 857.80M | 2.063 |
DOC
Healthpeak Properties Inc
|
19.49 | 13.35B | 2.87B | 250.10M | 1.13B | 0.3188 |
CTRE
Caretrust Reit Inc
|
41.52 | 9.72B | 522.75M | 333.94M | 397.14M | 1.5617 |
Ventas Inc Stock (VTR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-09 | Eingeleitet | Goldman | Buy |
| 2025-10-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-09-19 | Eingeleitet | UBS | Neutral |
| 2025-06-23 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2025-03-07 | Hochstufung | Argus | Hold → Buy |
| 2025-01-17 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2024-10-01 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-03-18 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2024-02-26 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-01-30 | Eingeleitet | Deutsche Bank | Buy |
| 2024-01-16 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-11-07 | Hochstufung | Wedbush | Neutral → Outperform |
| 2023-10-11 | Eingeleitet | Exane BNP Paribas | Outperform |
| 2023-10-03 | Eingeleitet | Wedbush | Neutral |
| 2023-09-20 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2023-08-11 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-06-23 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2023-04-20 | Eingeleitet | Wells Fargo | Overweight |
| 2022-11-01 | Bestätigt | Credit Suisse | Outperform |
| 2022-11-01 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2022-10-10 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2022-06-30 | Hochstufung | Jefferies | Hold → Buy |
| 2022-06-23 | Eingeleitet | Credit Suisse | Outperform |
| 2022-06-03 | Eingeleitet | CapitalOne | Overweight |
| 2022-05-18 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2022-03-11 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2022-03-11 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-02-01 | Eingeleitet | Credit Suisse | Neutral |
| 2022-01-20 | Hochstufung | Mizuho | Neutral → Buy |
| 2021-12-14 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-11-22 | Herabstufung | SMBC Nikko | Outperform → Neutral |
| 2021-10-04 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2021-09-23 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2021-09-07 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2021-08-26 | Hochstufung | BMO Capital Markets | Underperform → Market Perform |
| 2021-07-14 | Fortgesetzt | Mizuho | Neutral |
| 2021-06-15 | Eingeleitet | Wolfe Research | Outperform |
| 2021-06-11 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2021-05-13 | Hochstufung | KeyBanc Capital Markets | Underweight → Overweight |
| 2021-05-13 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2021-01-08 | Herabstufung | BMO Capital Markets | Market Perform → Underperform |
| 2021-01-06 | Eingeleitet | Robert W. Baird | Neutral |
| 2020-11-30 | Hochstufung | BofA Securities | Underperform → Buy |
| 2020-11-10 | Hochstufung | Jefferies | Underperform → Hold |
| 2020-09-08 | Herabstufung | Argus | Buy → Hold |
| 2020-09-02 | Fortgesetzt | Stifel | Hold |
| 2020-08-20 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2020-08-14 | Hochstufung | Evercore ISI | Underperform → In-line |
| 2020-08-14 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-06-15 | Herabstufung | Evercore ISI | In-line → Underperform |
| 2020-03-25 | Hochstufung | Raymond James | Mkt Perform → Strong Buy |
| 2020-03-23 | Herabstufung | BofA/Merrill | Neutral → Underperform |
| 2020-03-10 | Herabstufung | Jefferies | Buy → Underperform |
| 2020-02-28 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2020-01-22 | Herabstufung | Raymond James | Mkt Perform → Underperform |
| 2020-01-17 | Hochstufung | Jefferies | Hold → Buy |
| 2019-12-20 | Fortgesetzt | Mizuho | Neutral |
| 2019-12-10 | Herabstufung | Wells Fargo | Market Perform → Underperform |
| 2019-11-19 | Hochstufung | Argus | Hold → Buy |
| 2019-10-30 | Herabstufung | Stifel | Buy → Hold |
| 2019-10-28 | Herabstufung | CapitalOne | Overweight → Equal Weight |
| 2019-10-28 | Herabstufung | Citigroup | Buy → Neutral |
Alle ansehen
Ventas Inc Aktie (VTR) Neueste Nachrichten
Ventas stock (US92276F1003): Q1 results highlight senior housing growth - AD HOC NEWS
Ventas stock (US92276F1003): healthcare REIT updates investors after latest quarterly results - AD HOC NEWS
AlphaCore Capital LLC Invests $1.26 Million in Ventas, Inc. $VTR - MarketBeat
Here is Why Ventas (VTR) is One of the Best Large Cap Stocks to Buy Under $100 - Insider Monkey
Ventas Expands Equity Program And Confirms Governance Stability Might Change The Case For Investing In Ventas (VTR) - simplywall.st
Ventas Inc. stock (US92276F1003): Latest company update and what investors are watching - AD HOC NEWS
Ventas Expands ATM Program to Bolster Capital Flexibility - The Globe and Mail
Ventyx Biosciences stock (US92276F1003): clinical setbacks keep investors on edge - AD HOC NEWS
(VTR) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
ANTIPODES PARTNERS Ltd Sells 243,423 Shares of Ventas, Inc. $VTR - MarketBeat
Ventas to buy 85 per cent of Le Groupe Maurice for $2B - RENX
Ventas, Inc. Announces SEC Filing and Dealer Agreements for Common Stock (VTR) on NYSE - Minichart
Ventas director Rakowich sells $103,915 in company stock - Investing.com UK
Ventas director Rakowich sells $103,915 in company stock By Investing.com - Investing.com Australia
Ventas updates ATM sales agreement and announces annual meeting results - Investing.com
Insider Selling: Ventas (NYSE:VTR) Director Sells 1,152 Shares of Stock - MarketBeat
Ventas's Peter J. Bulgarelli to Receive Prorated 2026 Bonus upon Retirement - TradingView
Ventas (NYSE: VTR) updates ATM program — up to $3.0B common stock available - Stock Titan
Ventas (VTR) director awarded 2,047 restricted stock units under 2022 plan - Stock Titan
Ventas (VTR) boosts $3B ATM equity capacity and confirms 2026 vote results - Stock Titan
Ventas IncEnters amendment no. 3 to ATM sales agreement on May 15, 2026SEC filing - marketscreener.com
Ventas, Inc. (NYSE: VTR) director receives 2,047-share stock award - Stock Titan
Director Sumit Roy receives 2,047-share equity award at Ventas (NYSE: VTR) - Stock Titan
Ventas (NYSE: VTR) director sells 1,152 shares, receives 2,047 RSUs - Stock Titan
Ventas (VTR) director Sean P. Nolan receives 2,047 restricted stock units grant - Stock Titan
Ventas (VTR) director Marguerite Nader awarded 2,047 restricted stock units - Stock Titan
Ventas (VTR) director Roxanne Martino receives 2,047 restricted stock units grant - Stock Titan
Ventas (VTR) director Matthew Lustig receives 2,047 restricted stock units grant - Stock Titan
Ventas (VTR) director receives 2,047 RSUs under 2022 incentive plan - Stock Titan
Ventas (VTR) director Theodore Bigman receives 2,047 restricted stock units grant - Stock Titan
Director Melody Barnes gains 2,047 RSUs at Ventas (VTR) - Stock Titan
Ventas Inc. stock underperforms Friday when compared to competitors - MarketWatch
Ventas (NYSE: VTR) reports $79.97M in Form 13F holdings - Stock Titan
Ventas Stock Has Surged 45% in 12 Months. Does the Valuation Still Hold Up in 2026? - TIKR.com
Ventas (VTR) Stock Price, News & Analysis $VTR - MarketBeat
Ventas Inc. stock (US92276F1003): REIT deal activity keeps the US senior housing story in focus - AD HOC NEWS
[144] Ventas, Inc. SEC Filing - Stock Titan
Ventyx Biosciences stock (US92276F1003): Acquired by Eli Lilly for $1.2B in January - AD HOC NEWS
Ventas stock (US92276F1003): Maintains $0.52 quarterly dividend - AD HOC NEWS
Ventas Inc To Go Ex-Dividend On June 30th, 2026 With 0.52 USD Dividend Per Share - 富途牛牛
Ventas declares $0.52 quarterly dividend per share By Investing.com - Investing.com South Africa
Ventas declares $0.52 quarterly dividend per share - Investing.com
Ventas Keeps Quarterly Dividend at $0.52 a Share, Payable July 16 to Shareholders of Record on June 30 - marketscreener.com
Ventas Inc. stock outperforms competitors on strong trading day - MarketWatch
Ventas Declares Quarterly Dividend of $0.52 Per Common Share - The Joplin Globe
Ventas, Inc. Declares Quarterly Dividend, Payable on July 16, 2026 - marketscreener.com
Ventas stock (US92276F1003): Jefferies lifts price target to $100 - AD HOC NEWS
Ventas stock (US92276F1003): Jefferies raises price target to $100 - AD HOC NEWS
Jefferies Adjusts Price Target on Ventas to $100 From $97, Maintains Buy Rating - marketscreener.com
Jefferies Maintains Ventas Inc(VTR.US) With Buy Rating, Raises Target Price to $100 - Moomoo
VTR Technical Analysis | Trend, Signals & Chart Patterns | VENTAS INC (NYSE:VTR) - ChartMill
Finanzdaten der Ventas Inc-Aktie (VTR)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.09%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):